Published online Jul 28, 2015.
https://doi.org/10.4168/aard.2015.3.4.294
Successful rapid desensitization for cetuximab-induced anaphylaxis
Abstract
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Table 1
The preparation of 4-bottle tenfold increasing solutions used in the rapid 12-step desensitization protocol in the present case of the cetuximab-induced delayed hypersensitivity
This study was supported by a grant from Ministry of Food and Drug Safety to operation of the Regional Pharmacovigilance Center in 2015.
References
-
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373–380.
-
-
Lee SY, Yang MS, Jung JW, Oh MJ, Park CH, Sohn SW, et al. Updates on desensitization for hypersensitivity reactions related to chemotherapy. Allergy Asthma Respir Dis 2013;1:295–302.
-
-
Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013;68:853–861.
-
-
Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol 2007;5:451–457.
-